Dynavax Technologies | DVAX - Gross Profit On Sales



Dynavax Technologies reported $78.57M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Adma Biologics USD 67.23M 3.9M Jun/2025
Amgen USD 6.17B 624M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Glaxosmithkline GBP 5.83B 232M Jun/2025
Merck USD 12.99B 224M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sarepta Therapeutics USD 457.87M 149.43M Jun/2025
TG Therapeutics USD 122.21M 16.9M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025